

**Bjoern Riefke, Head of Metabolic Profiling and Clinical Pathology, Bayer Schering Pharma**

After the study of Biology and his PhD in Zoology/Animal Physiology at the Heinrich-Heine-University in Duesseldorf, Germany Bjoern Riefke started to work as a research fellow in 1994 at the Institute of Diagnostic Research in Berlin. His main research field was the biological characterization of dyes for near-infrared in-vivo imaging. In 1998 he followed an offer of Schering AG to lead a research group at Justesa Imagen S.A. in Madrid, Spain as assistant manager and head of biological research and development in the field of X-ray contrast media research. In 2003 he moved back to Bayer Health Care Berlin (former Schering AG) and headed the group of early and mechanistic toxicology with research support for the early detection of safety liabilities of drug candidates and one year later headed the group of clinical pathology with the establishment of metabolic profiling technology in toxicology. Since 2005 he participated in the validation of new biomarkers within the HESI Nephrotoxicity Working Group. Beside the routine support and project related work the main area of interest are the application of metabolic profiling in toxicology and in pharmacological studies and the evaluation of new biomarkers for different organ toxicities in comparison to traditional endpoints of clinical pathology and histopathology in the context of toxicology testing.